Comparison of the AmpFire® Multiplex HPV Assay to the Xpert® HPV Assay for detection of human papillomavirus and cervical disease in women with human immunodeficiency virus: a pragmatic performance evaluation

[1] Catarino R(2015)Cervical cancer screening in developing countries at a crossroad: emerging technologies and policy choices World J Clin Oncol 6 281-290

[2] Petignat P(2010)Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection J Natl Cancer Inst 102 315-324

[3] Dongui G(2021)Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country PLoS ONE 16 e0251688-e21

[4] Vassilakos P(2016)Clinical significance of human papillomavirus genotyping J Gynecol Oncol 27 e21-512

[5] Rodríguez AC(2012)Importance of HPV genotyping for the screening, therapy and management of cervical neoplasias Geburtshilfe Frauenheilkd 72 507-20

[6] Schiffman M(2017)Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery Gynecol Oncol Rep 22 16-2412

[7] Herrero R(2017)Cervical cancer: a global health crisis Cancer 123 2404-1095

[8] Hildesheim A(2021)2020 list of human papillomavirus assays suitable for primary cervical cancer screening Clin Microbiol Infect 27 1083-262

[9] Bratti C(2012)A review of methods for detect human Papillomavirus infection Virol J 9 262-292

[10] Sherman M(2019)A review of the FDA-approved molecular testing platforms for human papillomavirus J Am Soc Cytopathol 8 284-172

[1] Catarino R(2015)Cervical cancer screening in developing countries at a crossroad: emerging technologies and policy choices World J Clin Oncol 6 281-290

[2] Petignat P(2010)Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection J Natl Cancer Inst 102 315-324

[3] Dongui G(2021)Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country PLoS ONE 16 e0251688-e21

[4] Vassilakos P(2016)Clinical significance of human papillomavirus genotyping J Gynecol Oncol 27 e21-512

[5] Rodríguez AC(2012)Importance of HPV genotyping for the screening, therapy and management of cervical neoplasias Geburtshilfe Frauenheilkd 72 507-20

[6] Schiffman M(2017)Cervical cancer in low and middle income countries: addressing barriers to radiotherapy delivery Gynecol Oncol Rep 22 16-2412

[7] Herrero R(2017)Cervical cancer: a global health crisis Cancer 123 2404-1095

[8] Hildesheim A(2021)2020 list of human papillomavirus assays suitable for primary cervical cancer screening Clin Microbiol Infect 27 1083-262

[9] Bratti C(2012)A review of methods for detect human Papillomavirus infection Virol J 9 262-292

[10] Sherman M(2019)A review of the FDA-approved molecular testing platforms for human papillomavirus J Am Soc Cytopathol 8 284-172